NASDAQ: KZRKezar Life Sciences Inc Stock
$4.16+0.10 (+2.46%)
Updated Apr 17, 2025
KZR Price
$4.16
Fair Value Price
$0.42
Market Cap
$30.39M
52 Week Low
$3.62
52 Week High
$9.18
P/E
-0.36x
P/B
0.26x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$83.74M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$74M
Beta
0.91
Next Earnings
Jun 18, 2025
Ex-Dividend
N/A
Next Dividend
N/A
KZR Overview
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KZR's potential to beat the market
- KZR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KZR
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important KZR news, forecast changes, insider trades & much more!
KZR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KZR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KZR ($4.16) is overvalued by 888.51% relative to our estimate of its Fair Value price of $0.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KZR ($4.16) is not significantly undervalued (888.51%) relative to our estimate of its Fair Value price of $0.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KZR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KZR due diligence checks available for Premium users.
Valuation
KZR fair value
Fair Value of KZR stock based on Discounted Cash Flow (DCF)
Price
$4.16
Fair Value
$0.42
Overvalued by
888.51%
KZR ($4.16) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KZR ($4.16) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KZR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KZR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.36x
Industry
-177.72x
Market
27.98x
KZR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.26x
Industry
4.05x
KZR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KZR's financial health
Profit margin
Revenue
$0.0
Net Income
-$20.2M
Profit Margin
0%
KZR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$144.7M
Liabilities
$27.8M
Debt to equity
0.24
KZR's short-term assets ($137.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KZR's short-term assets ($137.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KZR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KZR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.8M
Investing
$23.7M
Financing
$47.0k
KZR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KZR vs Biotech Stocks
Kezar Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.